Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Specific PHGKB|Pharmacogenomics PHGKB|PHGKB

Last Posted: Jun 29, 2022
spot light Spotlight

miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.
Tsermpini Evangelia Eirini et al. The pharmacogenomics journal 2022 6

We provide herein a detailed overview of circulating miRNAs and their expression profiles as biomarkers in schizophrenia, bipolar disorder and major depressive disorder and their role in response to specific treatments. Bioinformatics analysis of miR-34a, miR-106, miR-134 and miR-132, which are common among SZ, BD and MDD patients, showed brain enrichment and involvement in the modulation of critical signaling pathways, which are often deregulated in psychiatric disorders. We propose that specific miRNAs support accurate diagnosis and effective precision treatment of psychiatric disorders.

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.
Islam Farhana et al. The pharmacogenomics journal 2022 6

Results showed that individuals carrying the HLA-DRB1*04:02 allele had nearly sixfold (95% CI 2.20–15.80, pcorrected?=?0.03) higher odds of CIA with a negative predictive value of 99.3%. Previously unreplicated alleles, TNFb5, HLA-B*59:01, TNFb4, and TNFd3 showed significant associations with CIA after multiple-testing corrections. Our findings suggest that a predictive HLA-DRB1*04:02-based pharmacogenomic test may be promising for clinical implementation but requires further investigation.

Computational drug repurposing based on electronic health records: a scoping review
N Zhong et al, NPJ Digital Medicine, June 14, 2022

Computational drug repurposing methods adapt Artificial intelligence (AI) algorithms for the discovery of new applications of approved or investigational drugs. Among the heterogeneous datasets, electronic health records (EHRs) datasets provide rich longitudinal and pathophysiological data that facilitate the generation and validation of drug repurposing. Here, we present an appraisal of recently published research on computational drug repurposing utilizing the EHR.

Using genomics to improve drug prescribing
L Blackburn, PHG Foundation, April 2022

Some pharmacogenomic testing is already available. An NHS England pharmacogenetics test evaluation working group reviews evidence for the potential inclusion of new pharmacogentic tests in the National Genomic Medicine Test Directory. The report identified a number of barriers towards wider adoption of pharmacogenomic tests, including making the most of research evidence, poor availability of tests, health professional education and engagement, and making pharmacogenomic information readily available, for example through electronic systems.

news Latest News and Publications
Experience with comprehensive pharmacogenomic multi-gene panel in clinical practice: a retrospective single-center study. External Web Site Icon
Matišic Vid et al. Croatian medical journal 2022 63(3) 257-264
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. External Web Site Icon
Brooks Gabriel A et al. Clinical colorectal cancer 2022
Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. External Web Site Icon
Eadon Michael T et al. Contemporary clinical trials 2022 119106813
Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships. External Web Site Icon
Saugstad Austin A et al. Frontiers in genetics 2022 13857120
Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. External Web Site Icon
Blagec Kathrin et al. PloS one 2022 17(6) e0268534
Pharmacogenomics: a tool to improve medication safety and efficacy in patients with cystic fibrosis. External Web Site Icon
Sakon Colleen M et al. Pharmacogenomics 2022
Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. External Web Site Icon
Dong Olivia M et al. European heart journal. Quality of care & clinical outcomes 2022
Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients. External Web Site Icon
Grimsrud Kristin N et al. Journal of burn care & research : official publication of the American Burn Association 2022
Association of a Common NOS1AP Variant with Attenuation of QTc Prolongation in Men with Heroin Dependence Undergoing Methadone Treatment. External Web Site Icon
Chang Kuan-Cheng et al. Journal of personalized medicine 2022 12(5)
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping. External Web Site Icon
White Cassandra et al. Clinical pharmacology and therapeutics 2022


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.